^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NBEA-ALK fusion + EML4-ALK fusion

    i
    Other names: NBEA, Neurobeachin, BCL8B, LYST2, KIAA1544, Lysosomal-Trafficking Regulator, FLJ10197, Protein BCL8B, NEDEGE, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, EML4, EMAP Like 4, Restrictedly Overexpressed Proliferation-Associated Protein, Echinoderm Microtubule-Associated Protein-Like 4, Echinoderm Microtubule Associated Protein Like 4, Ropp 120, C2orf2, EMAP-4, EMAPL4, ROPP120, ELP120
    Entrez ID:
    238; 27436; 26960
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. (PubMed, Lung Cancer)
    This is the first report on one patient with a novel NBEA-ALK, EML4-ALK double-ALK fusion beneficial from alectinib. Alectinib may be a viable therapeutic option for NSCLC patients with double-ALK fusion, and liquid biopsy could dynamically monitor clinical curative effect.
    Clinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • NBEA (Neurobeachin)
    |
    ALK rearrangement • EML4-ALK fusion • ALK fusion • NBEA-ALK fusion + EML4-ALK fusion
    |
    Alecensa (alectinib)